Your browser doesn't support javascript.
loading
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Lu, Hengyu; Liu, Chen; Velazquez, Roberto; Wang, Hongyun; Dunkl, Lukas Manuel; Kazic-Legueux, Malika; Haberkorn, Anne; Billy, Eric; Manchado, Eusebio; Brachmann, Saskia M; Moody, Susan E; Engelman, Jeffrey A; Hammerman, Peter S; Caponigro, Giordano; Mohseni, Morvarid; Hao, Huai-Xiang.
Afiliación
  • Lu H; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Liu C; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Velazquez R; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Wang H; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Dunkl LM; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland.
  • Kazic-Legueux M; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland.
  • Haberkorn A; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland.
  • Billy E; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland.
  • Manchado E; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland.
  • Brachmann SM; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland.
  • Moody SE; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Engelman JA; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Hammerman PS; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Caponigro G; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Mohseni M; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Hao HX; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts. huaixiang.hao@novartis.com.
Mol Cancer Ther ; 18(7): 1323-1334, 2019 07.
Article en En | MEDLINE | ID: mdl-31068384
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Acrilonitrilo / Proteínas Proto-Oncogénicas p21(ras) / Proteína Tirosina Fosfatasa no Receptora Tipo 11 / Compuestos de Anilina / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Acrilonitrilo / Proteínas Proto-Oncogénicas p21(ras) / Proteína Tirosina Fosfatasa no Receptora Tipo 11 / Compuestos de Anilina / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2019 Tipo del documento: Article